Immune Tolerance Induction for Patients with Severe Hemophilia A: a Critical Literature Review

Overview

Journal J Thromb Thrombolysis

Specialty Cardiology & Vascular Diseases

Date 2011 Aug 6

PMID 21818664

Citations 8

Authors

Massimo Franchini

Giuseppe Lippi

Affiliations

Soon will be listed here.

Abstract

The development of inhibitors that neutralize the function of clotting factor VIII (FVIII) is currently the most challenging complication associated with the treatment of hemophilia A as it increases the disease-related morbidity and mortality. Immune tolerance induction (ITI) is the only documented strategy to eradicate persistent inhibitors in severe hemophilia A patients. Several studies have been conducted so far to identify patient- and treatment-related factors associated with greater ITI success. The currently available literature on ITI in hemophilia A will be critically reviewed in this article. In particular, we will focus on the role of the type of FVIII product on ITI outcome by analyzing the clinical and experimental data.

Citing Articles

The role of emicizumab, a bispecific factor IXa- and factor X-directed antibody, for the prevention of bleeding episodes in patients with hemophilia A.

Knight T, Callaghan M Ther Adv Hematol. 2018; 9(10):319-334.

PMID: 30344994 PMC: 6187429. DOI: 10.1177/2040620718799997.

Factors affecting the quality, safety and marketing approval of clotting factor concentrates for haemophilia.

Farrugia A, Liumbruno G, Candura F, Profili S, Cassar J Blood Transfus. 2018; 16(6):525-534.

PMID: 30201084 PMC: 6214824. DOI: 10.2450/2018.0150-18.

Issues in assessing products for the treatment of hemophilia - the intersection between efficacy, economics, and ethics.

Farrugia A, Noone D, Schlenkrich U, Schlenkrich S, OMahony B, Cassar J J Blood Med. 2015; 6:185-95.

PMID: 26124687 PMC: 4476485. DOI: 10.2147/JBM.S79091.

Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B.

Athale A, Marcucci M, Iorio A Cochrane Database Syst Rev. 2014; (4):CD010561.

PMID: 24763974 PMC: 8922972. DOI: 10.1002/14651858.CD010561.pub2.

Factor VIII inhibitors in hemophilia A: rationale and latest evidence.

Witmer C, Young G Ther Adv Hematol. 2013; 4(1):59-72.

PMID: 23610614 PMC: 3629762. DOI: 10.1177/2040620712464509.

References

Callaghan M, Rajpurkar M, Chitlur M, Warrier I, Lusher J . Immune tolerance induction in 31 children with haemophilia A: is ITI less successful in African Americans?. Haemophilia. 2010; 17(3):483-9. DOI: 10.1111/j.1365-2516.2010.02429.x. View

Kurth M, DiMichele D, Sexauer C, Sanders J, Torres M, Zappa S . Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors. Haemophilia. 2007; 14(1):50-5. DOI: 10.1111/j.1365-2516.2007.01560.x. View

DiMichele D . The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy. Haemophilia. 2008; 15(1):320-8. DOI: 10.1111/j.1365-2516.2008.01880.x. View

Salomon O, Zivelin A, Livnat T, Dardik R, Loewenthal R, Avishai O . Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency. Blood. 2003; 101(12):4783-8. DOI: 10.1182/blood-2002-09-2794. View

Dasgupta S, Repesse Y, Bayry J, Navarrete A, Wootla B, Delignat S . VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood. 2006; 109(2):610-2. DOI: 10.1182/blood-2006-05-022756. View

Barnes C, Rivard G, Poon M, Teitel J, Pai M, Kern M . Canadian multi-institutional survey of immune tolerance therapy (ITT) -- experience with the use of recombinant factor VIII for ITT. Haemophilia. 2006; 12(1):1-6. DOI: 10.1111/j.1365-2516.2005.01167.x. View

Lin Y, Yang X, Chevrier M, Craven S, Barrowcliffe T, Lemieux R . Relationships between factor VIII:Ag and factor VIII in recombinant and plasma-derived factor VIII concentrates. Haemophilia. 2004; 10(5):459-69. DOI: 10.1111/j.1365-2516.2004.00957.x. View

Valentino L, Recht M, Dipaola J, Shapiro A, Pipe S, Ewing N . Experience with a third generation recombinant factor VIII concentrate (Advate) for immune tolerance induction in patients with haemophilia A. Haemophilia. 2009; 15(3):718-26. DOI: 10.1111/j.1365-2516.2008.01960.x. View

Kempton C, White 2nd G . How we treat a hemophilia A patient with a factor VIII inhibitor. Blood. 2008; 113(1):11-7. DOI: 10.1182/blood-2008-06-160432. View

10.

Lusher J, Arkin S, Abildgaard C, Schwartz R . Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med. 1993; 328(7):453-9. DOI: 10.1056/NEJM199302183280701. View

11.

Santagostino E, Mannucci P, Bianchi Bonomi A . Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy. Haemophilia. 2000; 6(1):1-10. DOI: 10.1046/j.1365-2516.2000.00361.x. View

12.

Coppola A, Di Minno M, Santagostino E . Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches. Br J Haematol. 2010; 150(5):515-28. DOI: 10.1111/j.1365-2141.2010.08263.x. View

13.

Kallas A, Talpsep T . von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients. Haemophilia. 2001; 7(4):375-80. DOI: 10.1046/j.1365-2516.2001.00530.x. View

14.

Franchini M, Lippi G . Von Willebrand factor-containing factor VIII concentrates and inhibitors in haemophilia A. A critical literature review. Thromb Haemost. 2010; 104(5):931-40. DOI: 10.1160/TH10-03-0151. View

15.

Mauser-Bunschoten E, Nieuwenhuis H, Roosendaal G, van den Berg H . Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood. 1995; 86(3):983-8. View

16.

Nilsson I, Berntorp E, ZETTERVALL O . Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N Engl J Med. 1988; 318(15):947-50. DOI: 10.1056/NEJM198804143181503. View

17.

Haya S, Lopez M, Aznar J, Batlle J . Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish Registry. Haemophilia. 2001; 7(2):154-9. DOI: 10.1046/j.1365-2516.2001.00469.x. View

18.

Gringeri A, Mannucci P . Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors. Haemophilia. 2005; 11(6):611-9. DOI: 10.1111/j.1365-2516.2005.01161.x. View

19.

Oldenburg J, Schwaab R, Brackmann H . Induction of immune tolerance in haemophilia A inhibitor patients by the 'Bonn Protocol': predictive parameter for therapy duration and outcome. Vox Sang. 1999; 77 Suppl 1:49-54. DOI: 10.1159/000056717. View

20.

Astermark J, Voorberg J, Lenk H, DiMichele D, Shapiro A, Tjonnfjord G . Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro. Haemophilia. 2003; 9(5):567-72. DOI: 10.1046/j.1365-2516.2003.00802.x. View